| Literature DB >> 27992371 |
Zulong Xie1,2, Nana Dong1,3, Rong Sun1,3, Xinxin Liu1,3, Xia Gu4, Yong Sun1,3, Hongwei Du1,3, Jiannan Dai1,3, Youbin Liu1,3, Jingbo Hou1,3, Jinwei Tian1,3, Bo Yu1,3.
Abstract
Atherosclerosis often leads to myocardial infarction and stroke. We examined the influence of baseline plaque characteristics on subsequent vascular remodeling in response to changes in plaque size. Using optical coherence tomography (OCT) and intravascular ultrasound (IVUS), we examined 213 plaques from 138 patients with acute coronary syndrome at baseline and repeated IVUS at the 12-month follow-up. The change in external elastic membrane (EEM) area for each 1 mm2 change in plaque area (i.e., the slope of the regression line) was calculated as a measure of vascular remodeling capacity. In plaques with static positive remodeling, the slope was smaller than in plaques without static positive remodeling. In addition, the slope of the regression line for lesions with a large plaque burden was much smaller than that for lesions with a small plaque burden. Multivariate linear regression analysis showed that diabetes, calcification and static positive remodeling were inversely and independently associated with the level of change in EEM area/change in plaque area. Lesions with a large plaque burden, calcifications or static positive remodeling had less remodeling capacity, and calcification and static positive remodeling were independent predictors of reduced subsequent remodeling. Therefore, calcifications and static positive remodeling could be used as morphological biomarkers to predict decreased subsequent arterial remodeling.Entities:
Keywords: atherosclerosis; coronary artery remodeling; intravascular ultrasound; optical coherence tomography; plaque characteristics
Mesh:
Year: 2017 PMID: 27992371 PMCID: PMC5354827 DOI: 10.18632/oncotarget.13959
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Patient characteristics
| Variables | Values ( |
|---|---|
| Age (years) | 56.5 ± 9.3 |
| Male, | 96 (69) |
| Smoking, | 80 (58) |
| Diabetes mellitus, | 55 (40) |
| Hypertension, | 79 (57) |
| Hyperlipidemia, | 65 (47) |
| STEMI, | 33 (24) |
| NSTE-ACS, | 105 (76) |
| Concomitant medications | |
| Statins, | 130 (94) |
| Beta-blockers, | 82 (59) |
| ACEI or ARB, | 64 (46) |
| CCB, | 39 (28) |
| Aspirin, | 137 (99) |
| Clopidogrel, | 135 (98) |
Values are presented as the mean ± SD or n (%). ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; NSTE-ACS, non-ST-segment elevation acute coronary syndromes.
Laboratory values
| Variables | Baseline | Follow-up | |
|---|---|---|---|
| TC, mg/dl | 189.1 ± 41.8 | 147.3 ± 39.1 | <0.001 |
| LDL-C, mg/dl | 101.3 ± 30.9 | 75.4 ± 28.6 | <0.001 |
| HDL-C, mg/dl | 49.5 ± 12.4 | 45.6 ± 13.1 | <0.001 |
| TG, mg/dl | 188.7 ± 95.7 | 136.4 ± 100.1 | <0.001 |
| hs-CRP, mg/dl | 2.66 (0.94, 6.49) | 0.84 (0.52, 1.67) | <0.001 |
Categorical data are presented as n (%). Continuous data are presented as the mean ± SD or as median (25th, 75th). HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride.
Baseline angiographic and OCT-derived plaque characteristics
| Values ( | |
|---|---|
| Lesion location | |
| RCA, | 93 (44) |
| LAD, | 79 (37) |
| LCX, | 41 (19) |
| QCA findings | |
| MLD, mm | 1.86 ± 0.53 |
| RLD, mm | 3.09 ± 0.67 |
| DS, % | 40.3 ± 10.5 |
| Lesion length, mm | 10.8 ± 4.5 |
| OCT-derived plaque characteristics | |
| Lipid length, mm | 12.1 ± 7.3 |
| Lipid arc, ° | 192.4 ± 62.9 |
| Fibrous cap thickness, μm | 117.2 ± 74.9 |
| Fibrous plaque, | 61 (29) |
| TCFA, | 45 (21) |
| Microvessel, | 91 (43) |
| Cholesterol crystal, | 56 (26) |
| Calcification, | 82(39) |
| Macrophage, | 104 (49) |
Categorical data are presented as n (%). Continuous data are presented as the mean ± SD. MLD, minimum lumen diameter; RLD, reference lumen diameter; DS, diameter stenosis.
Baseline IVUS-derived plaque characteristics
| Values ( | |
|---|---|
| Lesion site | |
| EEM area, mm2 | 14.0 ± 5.05 |
| Lumen area, mm2 | 5.06 ± 2.10 |
| Plaque area, mm2 | 8.93 ± 3.84 |
| Plaque burden, % | 62.8 ± 10.4 |
| Static remodeling index | 0.97 ± 0.14 |
| Static positive remodeling, | 56 (26) |
| Spotty calcification, | 60 (28) |
| Attenuated plaque, | 53 (25) |
| Proximal reference site | |
| EEM area, mm2 | 15.8 ± 7.0 |
| Lumen area, mm2 | 8.17 ± 3.13 |
| Distal reference site | |
| EEM area, mm2 | 13.2 ± 4.9 |
| Lumen area, mm2 | 7.50 ± 3.11 |
Categorical data are presented as n (%). Continuous data are presented as the mean ± SD.
Mean EEM, lumen, and plaque areas
| Variables | Baseline | Follow-up | Change over time | |
|---|---|---|---|---|
| Mean EEM area, mm2 | 13.9 ± 4.7 | 13.5 ± 4.7 | −0.37 ± 1.76 | 0.002 |
| Mean lumen area, mm2 | 6.42 ± 2.32 | 6.29 ± 2.39 | −0.14 ± 1.32 | 0.133 |
| Mean plaque area, mm2 | 7.46 ± 3.06 | 7.23 ± 3.08 | −0.23 ± 1.02 | 0.001 |
Values are presented as the mean ± SD.
Figure 1Correlations of change in EEM area with change in plaque area according to OCT-derived plaque characteristics
The slopes, y-intercepts, and correlation coefficients are shown for all linear regression lines. *Comparison of the slopes of the regression lines.
Figure 2Correlations of change in EEM area with change in plaque area according to IVUS-derived plaque characteristics
The slopes, y-intercepts, and correlation coefficients are shown for all linear regression lines. N/A, not available; *comparison of the slopes of the regression lines.
Multivariate linear regression analysis of potential predictors for arterial remodeling capacity
| Variable | β | 95% CI | |
|---|---|---|---|
| Age | −0.436 | −0.891 – 0.020 | 0.061 |
| Male | 0.362 | −0.141 – 0.865 | 0.158 |
| Hyperlipidemia | 0.451 | −0.119 – 1.020 | 0.121 |
| Smoking | −0.301 | −0.788 – 0.187 | 0.227 |
| Diabetes mellitus | −0.704 | −1.181 – -0.228 | |
| Hypertension | −0.1 | −0.742 – 0.543 | 0.761 |
| ACEI/ARB | −0.056 | −0.578 – 0.465 | 0.833 |
| Beta-blockers | −0.317 | −0.768 – 0.134 | 0.168 |
| CCB | 0.331 | −0.290 – 0.952 | 0.296 |
| Statin | −0.615 | −1.891 – 0.661 | 0.345 |
| Baseline LDL-C | −0.342 | −0.893 – 0.210 | 0.225 |
| Baseline triglycerides | −0.177 | −0.704 – 0.350 | 0.511 |
| Baseline hs-CRP | −0.009 | −0.425 – 0.408 | 0.908 |
| Fibrous plaque | 0.071 | −0.464 – 0.606 | 0.795 |
| TCFA | −0.149 | −0.702 – 0.403 | 0.596 |
| Calcification | −0.601 | −1.044 – -0.157 | |
| Mircrovessel | −0.17 | −0.603 – 0.263 | 0.443 |
| Cholesterol crystal | −0.014 | −0.603 – 0.574 | 0.962 |
| Macrophage | 0.392 | −0.047 – 0.831 | 0.08 |
| Attenuated plaque | −0.019 | −0.541 – 0.504 | 0.944 |
| Positive remodeling | −0.508 | −1.018 – 0.002 | |
| Plaque burden | −0.106 | −0.587 – 0.374 | 0.665 |
| Plaque area | −0.005 | −0.714 – 0.704 | 0.989 |
| EEM area | −0.373 | −1.026 – 0.281 | 0.264 |
*The level of change in EEM area/change in plaque area represents the arterial remodeling capacity of each plaque.
Figure 3Representative OCT images
A. Fibrous plaque characterized by a homogeneous signal-rich area (red arrowheads). B. Measurement of lipid arc (yellow lines) and fibrous cap thickness (green line) for a lipid plaque. C. TCFA is defined by the presence of thin fibrous cap (< 65μm) overlying a lipid-rich plaque (maximum lipid arc > 90°) (white arrowheads). D. Microvessels are identified as signal-absent holes within a plaque (red arrows). E. Cholesterol crystals are defined as thin, linear regions of high signal intensity within a plaque (white arrowheads). F. Calcifications are identified as sharply demarcated areas with low signal attenuation (yellow arrows). Asterisk indicates guide-wire shadowing artifact.